Advertisement

Topics

Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate

09:18 EST 10 Nov 2017 | Speciality Pharma Journal

Paris, France and South San Francisco, Calif – November 9, 2017 – Sanofi will develop Principia Biopharma Inc.’s experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases. Under the license agreement signed this week, Sanofi will develop Principia’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246), which was designed …

Original Article: Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate

NEXT ARTICLE

More From BioPortfolio on "Sanofi Signs License Deal with Principia Biopharma for Multiple Sclerosis Drug Candidate"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...